ClinicalTrials.gg
RecruitingNCT06688903Updated Feb 25, 2025

App-based Diabetes Management and Community-based Interventions

An interventional study of App-based diabetes management and community-based health coaching in Diabetes Mellitus Type 2, sponsored by Singapore General Hospital. Recruiting at 2 sites in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-02-25.

Sponsored by Singapore General Hospital · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 10 months after the study started (first participant enrolled Jan 2024, registered Nov 2024).
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital — 5 open to participants now, 8 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Singapore General Hospital.

Planned enrollment
7th of 13
150 · median 150
Started
2024
with 1 other
No phase
13 of 15
5 open now
Registered
14th of 15
by date

Among the 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital, this one is the 7th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2024, is one of 13 with no phase, and was the 14th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital, or all of them as a file.
02

Study summary

Community-based health coaching interventions play a vital role in complementing the traditional chronic disease management model for type 2 diabetes patients. Compared to conventional approaches that often focus on periodic clinical visits, community-based coaching could provide continuous, personalised support within patients in everyday environments. Health coaches work directly with patients to set realistic goals, develop individualised action plans, and provide ongoing motivation and accountability. This personalised attention helps to improve self-management skills, such as medication adherence, dietary choices, and physical activity, which are crucial for chronic disease management and preventing complications. Our mobile health app, EMPOWER+ has multiple logging features, gamified elements to help users set goals and provide rewards, educational resources, and personalised nudges generated based on real users; inputs and predictive modeling. It has demonstrated some preliminary effectiveness and acceptability within the clinical settings. This trial aims to assess its effectiveness, adoption, and sustainability in the less-controlled community settings, preparing for its large implementation in the future.

03

Conditions studied

  • Diabetes Mellitus Type 2
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 21 years and above
  • Having been diagnosed with type 2 diabetes mellitus
  • Having most recent ≥ 6.5%
  • Physically able to exercise
  • Able to read, write, and converse in English
  • Able to comply with study procedures

Exclusion criteria

Exclusion Criteria:

  • Requiring assistance with basic activities of daily living (BADL)
  • Have planned major operation or surgical procedure within 6 months from the time of recruitment
  • Current pregnant or lactating
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Intervention

    Behavioral: App-based diabetes management and community-based health coaching

Interventions

  • BehavioralApp-based diabetes management and community-based health coaching

    All participants will use the EMPOWER+ app and a Fitbit wearable. They will also received community-based health coaching and/or other prescribed structured programmes.

06

What researchers measure

Primary outcomes

  1. HbA1c

    HbA1c over 6 months

    Time frame: 6 months

Secondary outcomes

  1. Physical activity as measured by number of steps

    Physical activity over 6 months

    Time frame: 6 months

  2. Physical activity as measured by moderate to vigorous active minutes

    Physical activity over 6 months

    Time frame: 6 months

  3. Physical activity as measured by GPAQ

    Physical activity as measured by GPAQ

    Time frame: 6 months

  4. Patient activation score as measured by patient activation measure

    Difference in patient activation score between intervention and control over 6 months

    Time frame: 6 months

  5. Medication adherence as measured by MARS-5

    Difference in medication adherence between intervention and control over 6 months

    Time frame: 6 months

  6. Quality of life as measured by EQ-5D-5L

    Difference in quality of life between intervention and control over 6 months

    Time frame: 6 months

  7. Healthcare cost as measured by cost of consultations, lab tests, medications, admission

    Healthcare cost over 6 months

    Time frame: 6 months

  8. Healthcare cost as measured by WPAI

    Healthcare cost over 6 months

    Time frame: 6 months

  9. Maintenance of the intervention effects on HbA1c

    HbA1c over 6 months after the 6-month intervention

    Time frame: 6 months

  10. Maintenance of the intervention effects on blood pressure

    Blood pressure over 6 months after the 6-month intervention

    Time frame: 6 months

  11. Maintenance of the intervention effects on total cholesterol

    Total cholesterol over 6 months after the 6-month intervention

    Time frame: 6 months

  12. Maintenance of the intervention effects on high-density lipoprotein (HDL)

    HDL over 6 months after the 6-month intervention

    Time frame: 6 months

  13. Maintenance of the intervention effects on low-density lipoprotein (LDL)

    LDL over 6 months after the 6-month intervention

    Time frame: 6 months

  14. Maintenance of the intervention effects on triglycerides

    Triglycerides over 6 months after the 6-month intervention

    Time frame: 6 months

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2025, 23 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 23 months is close to that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Nov 14, 2024
StartActual
Jan 6, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jun 30, 2026
Last update
Feb 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06688903
Responsible party
Sponsor
First posted
Nov 14, 2024
Start date
Jan 6, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Feb 25, 2025

Study contacts

Research coordinators
Contact
empower@singhealth.com.sg
6562223222

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion